Together, Los Angeles Cancer Network and Smilow Cancer Hospital at Yale New Haven add 30 ...
Independent DSMB identifies no safety concerns, and recommends continuation of BriaCell’s pivotal Phase 3 study ...
PHILADELPHIA and VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (Nasdaq: ...
Three BriaCell posters and one publish-only abstract highlight robust clinical data from Bria-IMT™ and Bria-OTS™ ...
Bria-OTS has cleared its safety evaluation in the Phase 1/2 study monotherapy dosage setting Phase ...
Phase 2 survival and clinical benefit data meet or exceed outcomes of FDA-approved therapies in ...
Repeated positive recommendation from Data Safety Monitoring Board (“DSMB”) of pivotal Phase 3 study for ...
October 8, 2015 Positive Release Testing Data From First Lot of Vaccine Submitted to FDA; ...
Accessibility Tools